Larimar Therapeutics Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
/ 
Frequently asked questions
To buy Larimar Therapeutics Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Larimar Therapeutics Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Larimar Therapeutics Inc. is LRMR:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Larimar Therapeutics Inc. has its primary listing on NASDAQ. You can trade Larimar Therapeutics Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Larimar Therapeutics Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Larimar Therapeutics Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Larimar Therapeutics Inc..